Market Research Logo

Global Intrauterine Contraceptive Devices (IUD) Market - Segmented by Type, Product, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Global Intrauterine Contraceptive Devices (IUD) Market - Segmented by Type, Product, and Geography - Growth, Trends, and Forecast (2018 - 2023)

The global intrauterine contraceptive devices market is expected to register a CAGR of 10% during the forecast period of 2018-2023. IUDs are small contraceptive devices, often T-shaped, containing either copper or levonorgestrel, which are inserted into the uterus. They are a form of long-acting contraception and are the most effective type of reversible birth control.

Technological Innovations

There are two types of IUDs: medicated (hormone releasing) or unmedicated (inert). The inert IUDs include copper-containing devices in a range of shapes and sizes and a non-medicated polyethylene device. The hormone releasing IUDs either release progesterone or levonorgestrel.

The main advantage of copper IUD is that it provides emergency contraception up to five days after unprotected sex. Currently, it is the most effective form of emergency contraception available. It prevents fertilization or implantation, but does not affect already implanted embryos. It does not contain any hormones and can therefore be used while breastfeeding. Additionally, fertility is regained quickly after the removal of IUD. Copper IUDs are also available in a wider range of sizes and shapes than hormonal IUDs.

The basic mechanism of action of hormonal IUDs is the thickening of cervical mucus, making it impenetrable to sperm. They also prevent ovulation in some users, reduce the ability of sperm to enter the ovum, and thin the endometrial lining. They help reduce or even prevent menstrual bleeding, and can be used to treat menorrhagia (heavy menses), once the pathologic causes of menorrhagia (such as uterine polyps) have been ruled out. These advancements in technology of IUDs are expected to drive the growth of the global IUD market.

Other factors, such as the increasing rate of unintended pregnancies, supportive government initiatives and private firms to prevent unwanted abortions and pregnancies, and effective contraception and less side effects of IUCD are boosting the growth of the market.

High Cost of Treatment

The IUD choice of method may not be opted often because of cost, which is a major constraint to the market’s growth. Mirena IUD costs approximately USD 400, whereas, Jaydess and copper IUDs cost about USD 325 and USD 80 respectively. Unless covered by insurance, these devices can seem expensive to the majority of the female population. The cost of IUD reflects the payment incurred on research and development, clinical trials, and FDA, by the manufacturers. The other reason for the high cost is the relative length of efficacy of IUDs. As they last for years, such products tend to cost more. However, they cause an economic burden on the women with relatively low or no income. Taking other factors into consideration, an IUD could cost a user as much as USD 1,000, if not covered by a health insurance plan. Some insurance companies are illegally denying coverage of expensive contraceptives like IUD, making it difficult for patients to acquire this safe, effective health-care product. The other factors, such as stringent regulatory and reimbursement policies and threat of causing pelvic inflammatory infection (PID) are hindering the market’s growth.

Asia-Pacific to Record a Robust CAGR

Due to the increasing unplanned pregnancy and adoption of these devices in the region, Asia-Pacific is expected to register a robust CAGR over the forecast period. Moreover, supportive government initiatives and policies focused on improved healthcare in Asian countries are also supporting the growth of the market. Currently, North America accounts for the largest share, followed by Europe.

Key Developments in the Market

  • December 2017 - Agile Therapeutics Inc. received a complete response letter from the FDA, for Twirla (AG200-15) for the prevention of pregnancy.
  • June 2017 - Johnson & Johnson acquired Actelion Company.
Major Players: AGILE THERAPEUTICS, ANI PHARMACEUTICALS INC., JOHNSON & JOHNSON LTD, BAYER HEALTHCARE, FUJI LATEX CO. LTD, MYLAN LABORATORIES, MERCK & CO., OKAMATO INDUSTRIES INC., PFIZER, and RECKITT BENCKISER GROUP PLC, among others.

Reasons to Purchase this Report
  • Current and future global intrauterine contraceptive devices (IUD) market outlook in the developed and emerging markets.
  • Analyzing various perspectives of the market, with the help of Porter’s five forces analysis.
  • The segment that is expected to dominate the market.
  • The regions that are expected to witness the fastest growth during the forecast period.
  • Identify the latest developments, market shares, and strategies employed by the major market players.
  • 3 months analyst support along with the Market Estimate sheet (in Excel).
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.


1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Technological Innovations
6.1.2 Increasing Rate of Unintended Pregnancies
6.1.3 Supportive Government Initiatives and Private Firms for the Prevention of Unwanted Abortions and Pregnancies
6.1.4 Effective Contraception and Less Side Effects
6.2 Market Restraints
6.2.1 High Cost of Treatment
6.2.2 Stringent Regulatory and Reimbursement Policies
6.2.3 Risk of Causing Pelvic Inflammatory Infection (PID)
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Hormonal Intrauterine Device
7.1.2 Copper Intrauterine Device
7.2 By Products
7.2.1 Mirena
7.2.2 Skyla
7.2.3 Paragard
7.2.4 Essure
7.2.5 Levosert
7.2.6 Other Products
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Merger & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Agile Therapeutics
9.2 ANI Pharmaceuticals Inc.
9.3 Bayer Healthcare
9.4 Fuji Latex Co. Ltd
9.5 Johnson & Johnson Ltd
9.6 Merck & Co.
9.7 Mylan Laboratories
9.8 Okamato Industries Inc.
9.9 Pfizer
9.10 Reckitt Benckiser Group PLC
* List Not Exhaustive
10. Future of the Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report